テザカフトル
- ¥165600 - ¥417600
- 化學(xué)名: テザカフトル
- 英語(yǔ)名: Tezacaftor
- 別名:テザカフトル
- CAS番號(hào): 1152311-62-0
- 分子式: C26H27F3N2O6
- 分子量: 520.5
- EINECS:
- MDL Number:MFCD23106064
2物価
選択條件:
ブランド
- 富士フイルム和光純薬株式會(huì)社(wako)
パッケージ
- 250mg
- 1g
- 生産者富士フイルム和光純薬株式會(huì)社(wako)
- 製品番號(hào)W01COBQJ-3441
- 製品説明
- 英語(yǔ)製品説明1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl}cyclopropane-1-carboxamide
- 包裝単位1g
- 価格¥417600
- 更新しました2021-03-23
- 購(gòu)入
- 生産者富士フイルム和光純薬株式會(huì)社(wako)
- 製品番號(hào)W01COBQJ-3441
- 製品説明
- 英語(yǔ)製品説明1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl}cyclopropane-1-carboxamide
- 包裝単位250mg
- 価格¥165600
- 更新しました2021-03-23
- 購(gòu)入
生産者 | 製品番號(hào) | 製品説明 | 包裝単位 | 価格 | 更新時(shí)間 | 購(gòu)入 |
---|---|---|---|---|---|---|
富士フイルム和光純薬株式會(huì)社(wako) | W01COBQJ-3441 | 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl}cyclopropane-1-carboxamide |
1g | ¥417600 | 2021-03-23 | 購(gòu)入 |
富士フイルム和光純薬株式會(huì)社(wako) | W01COBQJ-3441 | 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl}cyclopropane-1-carboxamide |
250mg | ¥165600 | 2021-03-23 | 購(gòu)入 |
プロパティ
沸點(diǎn) :610.8±55.0 °C(Predicted)
比重(密度) :1.49±0.1 g/cm3(Predicted)
貯蔵溫度 :Store at -20°C , stored under nitrogen
溶解性 :≥21.8 mg/mL in DMSO; insoluble in EtOH; ≥24.3 mg/mL in H2O
外見(jiàn) :solid
酸解離定數(shù)(Pka) :13.99±0.20(Predicted)
色 :White to yellow
InChIKey :MJUVRTYWUMPBTR-MRXNPFEDSA-N
SMILES :C1(C2=CC=C3OC(F)(F)OC3=C2)(C(NC2C(F)=CC3=C(C=2)C=C(C(C)(C)CO)N3C[C@@H](O)CO)=O)CC1
比重(密度) :1.49±0.1 g/cm3(Predicted)
貯蔵溫度 :Store at -20°C , stored under nitrogen
溶解性 :≥21.8 mg/mL in DMSO; insoluble in EtOH; ≥24.3 mg/mL in H2O
外見(jiàn) :solid
酸解離定數(shù)(Pka) :13.99±0.20(Predicted)
色 :White to yellow
InChIKey :MJUVRTYWUMPBTR-MRXNPFEDSA-N
SMILES :C1(C2=CC=C3OC(F)(F)OC3=C2)(C(NC2C(F)=CC3=C(C=2)C=C(C(C)(C)CO)N3C[C@@H](O)CO)=O)CC1
安全情報(bào)
絵表示(GHS): | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
注意喚起語(yǔ): | Warning | |||||||||||||||||||||||||||||||||||
危険有害性情報(bào): |
|
|||||||||||||||||||||||||||||||||||
注意書(shū)き: |
|
説明
Tezacaftor (VX-661) is an oral medication for cystic fibrosis (CF) developed by Vertex Pharmaceuticals. In a combination therapy formulation called Symdeko (tezacaftor plus ivacaftor), it is approved in the U.S. and Canada for CF patients, ages 12 and older, who have two copies of the F508del mutation in the CFTR gene and one minimal function mutation. Symdeko is approved and marketed in the EU as Symkevi.Tezacaftor is not approved as a stand-alone treatment, but as part of a combination therapy.関連商品価格
- CFTRinh-172
¥22700-284000 - ルマカフトル
¥20000-424600 - イバカフトール
¥42800-800000